AI assistant
Dechra Pharmaceuticals PLC Director's Dealing 2022
4797_dirs_2022-09-22_11a8083c-836f-4f2f-9829-08c40d2afb1f.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 3543A
Dechra Pharmaceuticals PLC
22 September 2022
22 September 2022
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
Dechra Pharmaceuticals PLC announces that on 20 September 2022, the following PDMRs acquired ordinary shares of 1p each in the Company pursuant to awards granted to them on 6 September 2019 under the Dechra Pharmaceuticals PLC Long Term Incentive Plan (the LTIP). The vesting of the awards was subject to the achievement of performance conditions which were satisfied to the extent that the awards vested at 65.5%.
| Name | Capacity | Shares acquired | Total beneficial shareholding following this announcement | Percentage of issued share capital |
| Ian Page | Director | 22,981 | 415,369 | 0.37% |
| Paul Sandland | Director | 3,999 | 13,650 | 0.01% |
| Tony Griffin | Director | 7,194 | 40,657 | 0.04% |
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.
Notification of Dealing Forms
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Ian Page | |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/PDMR | |
| b) | Initial notification/ amendment |
Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Acquisition of shares pursuant to the Company's Long Term Incentive Plan | |
| c) | Price(s) and volumes(s) | Price(s) £Nil Cost |
Volume(s) 22,981 |
| d) | Aggregated information - Aggregate volume - Price |
N/A | |
| e) | Date of the transaction | 2022.09.20 | |
| f) | Place of the transaction | Outside a trading venue |
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Paul Sandland | |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/PDMR | |
| b) | Initial notification/ amendment |
Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Acquisition of shares pursuant to the Company's Long Term Incentive Plan | |
| c) | Price(s) and volumes(s) | Price(s) £Nil Cost |
Volume(s) 3,999 |
| d) | Aggregated information - Aggregate volume - Price |
N/A | |
| e) | Date of the transaction | 2022.09.20 | |
| f) | Place of the transaction | Outside a trading venue |
| 1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | ||
| a) | Name | Tony Griffin | |
| 2. | Reason for the notification | ||
| a) | Position/status | Director/PDMR | |
| b) | Initial notification/ amendment |
Initial Notification | |
| 3. | Details of the Issuer | ||
| a) | Name | Dechra Pharmaceuticals PLC | |
| b) | LEI code | 213800J4UVB5OWG8VX82 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument Identification code |
Ordinary Shares of 1 pence each ISIN: GB0009633180 |
|
| b) | Nature of the transaction | Acquisition of shares pursuant to the Company's Long Term Incentive Plan | |
| c) | Price(s) and volumes(s) | Price(s) £nil |
Volume(s) 7,194 |
| d) | Aggregated information - Aggregate volume - Price |
N/A | |
| e) | Date of the transaction | 2022.09.20 | |
| f) | Place of the transaction | Outside a trading venue |
| For further information, please contact: |
| Melanie Hall, Company Secretary |
| Telephone: 01606 814730 |
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBSGDCBSDDGDD